๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pilot Trial on the Use of Etanercept and Methylprednisolone as Primary Treatment for Acute Graft-versus-Host Disease

โœ Scribed by Joseph P. Uberti; Lois Ayash; Voravit Ratanatharathorn; Samuel Silver; Christopher Reynolds; Michael Becker; Pavan Reddy; Kenneth R. Cooke; Gregory Yanik; Joel Whitfield; Dawn Jones; Raymond Hutchinson; Thomas Braun; James L.M. Ferrara; John E. Levine

Book ID
116278337
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
149 KB
Volume
11
Category
Article
ISSN
1083-8791

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

High dose bolus methylprednisolone for t
High dose bolus methylprednisolone for the treatment of acute graft versus host disease
โœ Bacigalupo, Andrea ;Lint, Maria T. ;Frassoni, Francesco ;Podesta, Marina ;Venezi ๐Ÿ“‚ Article ๐Ÿ“… 1983 ๐Ÿ› Springer-Verlag โš– 508 KB

Nineteen patients with acute graft versus host disease (GvHD) following bone marrow transplantation (BMT) were treated with high dose bolus 6-methylprednisolone (BMPr), at the dose of 20 mg/kg/day i.v. for the first 3 days, 10 mg/kg/day i.v. for the following 4 days, and then at doses gradually tape

Intra-arterial methylprednisolone for th
Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease
โœ Laurie A. Milner; Michael W. Becker; Steven H. Bernstein; Lauren Bruckner; Jonat ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 681 KB

Staging System and chromosomal abnormalities determined by standard metaphase karyotype and/or fluorescence in situ hybridization (FISH). Treatment-induced adverse events were graded according to the National Cancer Institute common terminology criteria for adverse events (CTCAE) version 4.0. For r